ArticleThe Lancet regional health. Southeast Asia2026
Two-day versus three-day systemic antibiotic prophylaxis for Gustilo-Anderson type IIIA and IIIB open tibial fractures (PROACT): a randomised controlled trial.
Article in The Lancet regional health. Southeast Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The optimal duration of systemic antibiotic prophylaxis (SAP) for Gustilo-Anderson type IIIA and IIIB open tibial fractures remains uncertain. We compared 2-day versus 3-day prophylaxis in patients treated at a level I trauma centre. Methods: The Prophylactic Antibiotic Course in Open Tibial Fractures (PROACT) trial was a pragmatic, single-centre, single-blinded randomised controlled trial conducted in India. Adults (≥18 years) with Gustilo-Anderson type IIIA or IIIB open tibial fractures were randomly assigned (1:1) to receive 2 days or 3 days of intravenous cefuroxime and amikacin; metronidazole was added for farm-related contamination. Outcome assessors were masked, and all patients received standardised orthoplastic care. The primary outcome was 90-day surgical-site infection (SSI). Analyses were by intention to treat. The trial was prospectively registered with the Clinical Trials Registry of India (CTRI/2020/06/026083) and is closed to recruitment. Findings: Between July 1, 2020, and Dec 31, 2022, 241 patients were assessed for eligibility, and 204 were randomly assigned to 2-day (n = 104) or 3-day (n = 100) prophylaxis; all were included in the primary analysis. SSI within 90 days occurred in 15 of 104 patients (14%) and 18 of 100 patients (18%), respectively (risk difference -3.6%, 95% CI -14.0 to 7.0; p = 0.60). Time-to-event analysis showed no statistically significant difference between groups (hazard ratio 1.22, 95% CI 0.60-2.46). Unplanned reoperation within 12 months occurred in 24 of 104 patients (23%) and 19 of 100 patients (19%). One patient in each group underwent secondary amputation due to flap failure. No treatment-related deaths were reported. Interpretation: Among adults with severe open tibial fractures managed with contemporary orthoplastic care, 2-day compared with 3-day SAP was not associated with a statistically significant difference in SSI. However, clinically meaningful benefit or harm cannot be excluded because of the limited sample size and imprecise estimates. Larger multicentre studies are warranted to confirm these findings. Funding: This study received no external funding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.